AzTrials
AzTrials

Pleural Effusion Associated With Pulmonary InfectionPhase 2[LYTICS+]NCT06713382

Evaluating the Efficacy and Safety of Saline Irrigation as an Add-On Therapy for Retained Pleural Infections [LYTICS +]

A Phase 2 study testing Pleural Saline Irrigation in people with Pleural Effusion Associated With Pulmonary Infection and Pleural Effusion Disorder, run by Beth Israel Deaconess Medical Center at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

The purpose of this protocol is to conduct a pilot prospective non-blind clinical trial to evaluate the efficacy and safety of a novel saline irrigation technique as an adjunct to standard interventions for treating retained pleural infections. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Pleural Saline Irrigation
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
96 participants
Where
1 siteUnited States
Study dates
10 Apr 2025to 20 Jan 2027
Phase
Phase 2

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥18 years.
  • Presence of purulent pleural fluid or pleural fluid analysis with any of the following:
  • pH ≤ 7.2.
  • Glucose < 40 mg/dL.
  • LDH > 1000 IU/L.
  • Presence of bacterial or fungal organisms on Gram stain or culture.
Show all 9Show fewer
  • Chest tube placement with less than 200 mL drainage in 24 hours.
  • Indication for IPFT treatment based on treating physician's criteria.
  • Radiographic evidence of septations on chest ultrasound (US) or loculations on low-dose chest computed tomography (CT).

Who cannot join

  • Inability to provide informed consent.
  • Pregnant patients.
  • Patients with significant comorbidities that may interfere with the study -outcomes (e.g., terminal malignancy).
  • Complicated sympathetic effusion.
  • Hepatic hydrothorax.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Adnan Majid, MD contact

6179016430

amajid@bidmc.harvard.edu

Maria C Lopez, MD contact

7869678448

mlopezgi@bidmc.harvard.edu

United States1 site, 1 recruiting
  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215

    Adnan Majid, MD, 6179016430, amajid@bidmc.harvard.edu

    Adnan Majid, MD

    Recruiting

Other trials in United States

About this study

Official title: Evaluating the Efficacy and Safety of Saline Irrigation as an Add-On Therapy for Retained Pleural Infections (LYTICS +)

The purpose of this protocol is to conduct a pilot prospective non-blind clinical trial to evaluate the efficacy and safety of a novel saline irrigation technique as an adjunct to standard interventions for treating retained pleural infections. Intrapleural fibrinolytic therapy (IPFT) is commonly used for infections not adequately managed with antibiotics and intercostal tube drainage, while saline irrigation serves as an alternative for cases with a high bleeding risk where IPFT is not feasible. The efficacy of saline irrigation combined with IPFT remains unexplored. The hypothesis is that saline irrigation could be an effective and safe addition to IPFT for patients with persistent pleural infections.

The specific aims of the study include:

Read more

Determine the efficacy of saline irrigation as add-on therapy to IPFT: Compare the clinical outcomes of patients receiving saline irrigation combined with IPFT to those receiving IPFT alone to determine if the addition of saline irrigation offers significant benefits. Outcomes include changes in inflammatory markers, imaging characteristics (echography and CT), volume of pleural fluid drained, chest tube duration, hospital length of stay, and the need for subsequent surgical intervention.

Assess the safety and tolerability of saline irrigation plus IPFT: Compare complications and patient comfort in those receiving saline irrigation combined with IPFT to those receiving IPFT alone.

Read the detailed description

Objective:

To evaluate the efficacy and safety of pleural saline irrigation as an adjunct therapy in patients with retained pleural infection, comparing it with the standard of care (antibiotics, chest tube placement, and lytics).

Study Design:

This is a prospective, two-arm pilot trial to be conducted at Beth Israel Deaconess Medical Center. The study will involve two groups: one receiving standard care and the other receiving pleural saline irrigation in addition to standard care. Patients will be assigned to one of the two study arms (standard care vs. standard care + saline irrigation) using block randomization to ensure balanced group sizes.

Interventions:

Control Group (Standard Care):

Patients will receive the current standard of care, which includes antibiotics, chest tube placement, and intrapleural tPA/DNase therapy based on the criteria outlined above.

Intervention Group (Standard Care + Saline Irrigation):

In addition to the standard care, patients in this group will receive pleural saline irrigation through the chest tube immediately after IPFT. The amount of saline will be determined by free-flow saline infusion up to 250 mL. This maneuver will be repeated each time IPFT is administered, based on the treating physician's criteria.

Outcomes:

Primary Endpoint:

The primary outcome is the reduction in pleural effusion volume, measured with CT (volumetry) and US (Balik formula), with efficacy defined as a 10% or greater improvement compared to standard care alone. Success will be determined by a ≥10% additional reduction in pleural effusion volume compared to regular interventions.

Secondary Endpoints:

Rate of pleural infection resolution based on clinical (fever), radiographic (ultrasound and CT signs of complicated pleural effusion), and laboratory (inflammatory markers) data.

Chest tube duration. Duration of hospital stay. Complications related to the interventions. Pain associated with the interventions. Need for surgery. Overall mortality.

Data Collection and Variables:

A range of variables will be collected to assess both primary and secondary outcomes. Primary outcome measures will focus on the percentage reduction in pleural effusion volume, assessed through chest ultrasound or CT scan at baseline and during follow-up. Secondary outcomes include adverse events related to the intervention, such as hypothermia, chest discomfort, and fluid overload. The incidence of pleural infection-related complications, recurrence of infection, and the need for further pleural interventions, such as thoracentesis or chest tube placement, will be monitored. Chest tube duration, fever duration, leukocytosis, neutrophil count, and blood culture results will be evaluated to track infection resolution and patient recovery.

Subgroup analysis will be performed based on pleural fluid volume and characteristics (pH, glucose, LDH), antibiotic duration, and follow-up imaging results, both at the end of therapy and 3-6 weeks later. Other intervention-related variables, such as the amount and frequency of saline irrigation, chest tube size, intrapleural tPA/DNase doses, and the total volume of fluid drained, will also be collected to further assess the intervention's efficacy and safety.

Being tested
Pleural Saline Irrigation
Keywords
Pleural Effusion, Thoracentesis, Tissue Plasminogen Activator, DNase, Therapeutic Irrigation
Medical subject headings
Pleural Effusion

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Pleural Saline IrrigationCombination product

    This intervention, Pleural Saline Irrigation, involves the administration of up to 250 mL of sterile saline solution into the pleural cavity through a chest tube immediately following each intrapleural tPA/DNase (IPFT) therapy session. The saline irrigation is intended to aid in clearing infected pleural fluid and reducing pleural effusion volume. This maneuver is repeated based on the treating physician's criteria, differentiating it from standard care, which includes only antibiotics, chest tube placement, and IPFT without saline irrigation. The irrigation is expected to enhance infection resolution and may impact chest tube duration and the frequency of pleural interventions.

Study groups in NCT06713382
Study groupRoleWhat they receive
Standard of careNo interventionPatients will receive the current standard of care, which includes antibiotics, chest tube placement, and intrapleural tPA/DNase therapy based on their clinical criteria
Standard Care + Saline IrrigationExperimentalIn addition to the standard care, patients in this group will receive pleural saline irrigation through the chest tube immediately after IPFT. The amount of saline will be determined by free-flow saline infusion up to 250 mL. This maneuver will be repeated every time that IPFT is administered, based on treating physician's criteria
Receives: Combination Product: Pleural Saline Irrigation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Reduction in Pleural Effusion Volume

    This outcome assesses the percentage reduction in pleural effusion volume from baseline, measured by CT (volumetry) and ultrasound using the Balik formula. Efficacy is defined as a 10% or greater improvement in pleural effusion volume reduction in the intervention group (standard care plus pleural saline irrigation) compared to the control group (standard care alone). Success is determined by achieving a ≥10% additional reduction in pleural effusion volume in the intervention group compared to the control group, indicating a clinically meaningful improvement with adjunctive saline irrigation.

    Measured: Baseline (prior to intervention). During hospitalization (before each IPFT and irrigation session, anticipated every 24 hours, up to 14 days). At discharge (7-14 days post-intervention initiation). Follow-up at 3 weeks (+/- 3 days) and 6 weeks (+/- 3 day

Secondary outcomes (7)
  1. Rate of pleural infection resolution

    Determined through clinical markers (fever resolution), radiographic improvement (ultrasound and CT signs of effusion), and laboratory indicators (inflammatory markers and blood cultures).

    Measured: Baseline, at discharge (7-14 days post-intervention initiation), and follow-up (3 weeks +/- 3 days and 6 weeks +/- 3 days post-discharge).

  2. Chest tube duration

    Total duration of chest tube placement from insertion to removal.

    Measured: Through hospitalization (up to 14 days).

  3. Length of hospital stay

    Total length of stay from admission to discharge.

    Measured: Through hospitalization (anticipated 7-14 days).

  4. Complications related to the interventions

    Includes adverse events such as hypothermia, chest discomfort, fluid overload, and infection recurrence.

    Measured: During hospitalization (up to 14 days) and at follow-up (3 weeks +/- 3 days and 6 weeks +/- 3 days post-discharge).

  5. Pain associated with interventions

    Level of pain reported during procedures, measured using a standardized pain scale (e.g., Visual Analog Scale).

    Measured: During hospitalization (measured immediately after each intervention session, anticipated up to 14 days).

  6. Need for surgical intervention

    Incidence of surgical intervention required due to unresolved pleural infection or complications.

    Measured: Through study completion (up to 6 weeks post-discharge).

  7. Overall mortality

    Death from any cause during the study period.

    Measured: Through study completion (up to 6 weeks post-discharge).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Dec 2024
  2. Study start10 Apr 2025
  3. Primary completion20 Nov 2026 (estimated)
  4. Study completion20 Jan 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
\- Control Group (Standard Care): Patients will receive the current standard of care, which includes antibiotics, chest tube placement, and intrapleural tPA/DNase therapy based on the criteria outlined above. \- Intervention Group (Standard Care + Saline Irrigation): In addition to the standard care, patients in this group will receive pleural saline irrigation through the chest tube immediately after IPFT. The amount of saline will be determined by free-flow saline infusion up to 250 mL. This maneuver will be repeated every time that IPFT is administered, based on treating physician's criteria
Masking
None (open label)
Enrolment
96 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06713382
Sponsor's protocol ID
LYTICS+
Acronym
[LYTICS+]
Status last verified
Aug 2026
First submitted
15 Nov 2024
Last updated
28 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
Undecided

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in